GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tetraphase Pharmaceuticals Inc (NAS:TTPH) » Definitions » Operating Margin %

Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Operating Margin % : -698.80% (As of Mar. 2020)


View and export this data going back to 2013. Start your Free Trial

What is Tetraphase Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Tetraphase Pharmaceuticals's Operating Income for the three months ended in Mar. 2020 was $-12.26 Mil. Tetraphase Pharmaceuticals's Revenue for the three months ended in Mar. 2020 was $1.76 Mil. Therefore, Tetraphase Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2020 was -698.80%.

The historical rank and industry rank for Tetraphase Pharmaceuticals's Operating Margin % or its related term are showing as below:


TTPH's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -177.195
* Ranked among companies with meaningful Operating Margin % only.

Tetraphase Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Tetraphase Pharmaceuticals's Operating Income for the three months ended in Mar. 2020 was $-12.26 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2020 was $-60.76 Mil.


Tetraphase Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Tetraphase Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tetraphase Pharmaceuticals Operating Margin % Chart

Tetraphase Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -710.23 -1,512.73 -1,197.13 -387.65 -915.56

Tetraphase Pharmaceuticals Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,495.68 -2,107.36 -429.28 -682.96 -698.80

Competitive Comparison of Tetraphase Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Tetraphase Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tetraphase Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tetraphase Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Tetraphase Pharmaceuticals's Operating Margin % falls into.



Tetraphase Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Tetraphase Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2019 is calculated as

Operating Margin %=Operating Income (A: Dec. 2019 ) / Revenue (A: Dec. 2019 )
=-67.532 / 7.376
=-915.56 %

Tetraphase Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2020 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2020 ) / Revenue (Q: Mar. 2020 )
=-12.264 / 1.755
=-698.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tetraphase Pharmaceuticals  (NAS:TTPH) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Tetraphase Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Tetraphase Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
480 Arsenal Way, Suite 100, Watertown, MA, USA, 02472
Tetraphase Pharmaceuticals Inc is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize novel tetracyclines for serious and life-threatening conditions, including bacterial infections caused by multidrug-resistant, or MDR, bacteria. The company has developed its product, Xerava (eravacycline), a fully synthetic fluorocycline, as an intravenous, or IV antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections, or cIAI.
Executives
Guy Macdonald director C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Larry G. Edwards director, officer: See Remarks C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
L Patrick Gage director C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044
Steven Boyd director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director, 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc director, 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Nancy Wysenski director 2200 SUNBURST STREET, CHATSWORTH CA 90401
Garen G Bohlin director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER STREET, WALTHAM MA 02451
Geraldine Henwood director 88 SIDNEY ST, CAMBRIDGE MA 02139
Jeffrey Chodakewitz director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL ST., SUITE 101, WATERTOWN MA 02472
Kamalam Unninayar officer: Chief Financial Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Patrick Taylor Horn officer: Chief Medical Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
David Charles Lubner officer: SVP and CFO C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472

Tetraphase Pharmaceuticals (Tetraphase Pharmaceuticals) Headlines